These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36923472)

  • 41. Advances in AR-targeting chimeras: a case study of proteolysis-targeting chimeras from bench to bedside.
    Du W
    Future Med Chem; 2022 Oct; 14(20):1471-1489. PubMed ID: 36214138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteolysis targeting chimeras (PROTACs) in cancer therapy.
    Ocaña A; Pandiella A
    J Exp Clin Cancer Res; 2020 Sep; 39(1):189. PubMed ID: 32933565
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In Silico Modeling and Scoring of PROTAC-Mediated Ternary Complex Poses.
    Liao J; Nie X; Unarta IC; Ericksen SS; Tang W
    J Med Chem; 2022 Apr; 65(8):6116-6132. PubMed ID: 35412837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
    Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
    J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
    Yang C; Yang Y; Li Y; Ni Q; Li J
    J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
    Jin YH; Lu MC; Wang Y; Shan WX; Wang XY; You QD; Jiang ZY
    J Med Chem; 2020 May; 63(9):4644-4654. PubMed ID: 32153174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 48. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
    Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
    Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VHL-recruiting PROTAC attenuates renal fibrosis and preserves renal function via simultaneous degradation of Smad3 and stabilization of HIF-2α.
    Yang J; Ruan Y; Wang D; Fan J; Luo N; Chen H; Li X; Chen W; Wang X
    Cell Biosci; 2022 Dec; 12(1):203. PubMed ID: 36536448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants.
    Bemis TA; La Clair JJ; Burkart MD
    Chem Commun (Camb); 2021 Jan; 57(8):1026-1029. PubMed ID: 33406191
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies for designing proteolysis targeting chimaeras (PROTACs).
    He S; Dong G; Cheng J; Wu Y; Sheng C
    Med Res Rev; 2022 May; 42(3):1280-1342. PubMed ID: 35001407
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Balancing multiple objectives in conformation sampling to control decoy diversity in template-free protein structure prediction.
    Zaman AB; Shehu A
    BMC Bioinformatics; 2019 Apr; 20(1):211. PubMed ID: 31023237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Solution Conformations Shed Light on PROTAC Cell Permeability.
    Atilaw Y; Poongavanam V; Svensson Nilsson C; Nguyen D; Giese A; Meibom D; Erdelyi M; Kihlberg J
    ACS Med Chem Lett; 2021 Jan; 12(1):107-114. PubMed ID: 33488971
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PHOTACs Enable Optical Control of Protein Degradation.
    Reynders M; Trauner D
    Methods Mol Biol; 2021; 2365():315-329. PubMed ID: 34432252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Designing HDAC-PROTACs: lessons learned so far.
    Fischer F; Alves Avelar LA; Murray L; Kurz T
    Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities.
    Liu X; Wang A; Shi Y; Dai M; Liu M; Cai HB
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.